Mikhail Kosiborod

Mikhail Kosiborod

Cardiologist

Saint Luke’s Mid America Heart Institute, Kansas City, US

Biography

Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.

He is a cardiologist, Vice President of Research at Saint Luke's Health System, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. 

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

Read more

Media

Play Icon
The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

The PRESERVED-HF Study

Mikhail Kosiborod,

Federico M Asch, Jan Belohlavek, Rupert Bauersachs, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

thumbnail

Mikhail Kosiborod, Arun Sanyal ,

thumbnail

Mikhail Kosiborod, Arun Sanyal ,

End of Year COVID update with Dr Mikhail Kosiborod and Dr Shelley Zieroth

Mikhail Kosiborod, Shelley Zieroth,

Year End Video With Dr Mikhail Kosiborod And Dr Silvio Inzucchi

Mikhail Kosiborod, Silvio Inzucchi,

Mikhail Kosiborod, Mark Petrie,

DAPA-HF Background Therapy

Mikhail Kosiborod, Mark Petrie,

AHA 2019: Updates from the DAPA-HF trial — Dr Harriette Van Spall and Dr Mikhail N Kosiborod

Harriette Van Spall, Mikhail Kosiborod,

Andrew JS Coats, Carolyn Lam, Felipe Martínez, et al

EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

Mikhail Kosiborod,

DAPA-HF: A discussion with the trialist

John JV McMurray, Mikhail Kosiborod,

ACC 2018: SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs

Mikhail Kosiborod,